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Abstract
Background: Gas trapping quantified on chest CT scans has been proposed as a surrogate for small airway disease
in COPD. We sought to determine if measurements using paired inspiratory and expiratory CT scans may be better
able to separate gas trapping due to emphysema from gas trapping due to small airway disease.
Methods: Smokers with and without COPD from the COPDGene Study underwent inspiratory and expiratory chest
CT scans. Emphysema was quantified by the percent of lung with attenuation <−950HU on inspiratory CT. Four gas
trapping measures were defined: (1) Exp−856, the percent of lung < −856HU on expiratory imaging; (2) E/I MLA, the
ratio of expiratory to inspiratory mean lung attenuation; (3) RVC856-950, the difference between expiratory and
inspiratory lung volumes with attenuation between −856 and −950 HU; and (4) Residuals from the regression of
Exp−856 on percent emphysema.
Results: In 8517 subjects with complete data, Exp−856 was highly correlated with emphysema. The measures based
on paired inspiratory and expiratory CT scans were less strongly correlated with emphysema. Exp−856, E/I MLA and
RVC856-950 were predictive of spirometry, exercise capacity and quality of life in all subjects and in subjects without
emphysema. In subjects with severe emphysema, E/I MLA and RVC856-950 showed the highest correlations with
clinical variables.
Conclusions: Quantitative measures based on paired inspiratory and expiratory chest CT scans can be used as
markers of small airway disease in smokers with and without COPD, but this will require that future studies acquire
both inspiratory and expiratory CT scans.
Keywords: Emphysema, Chest CT scan, Small airways, Lung function tests, Smoking
Introduction
The small airways (<2 mm diameter) are the predominant
site of airflow limitation in chronic obstructive pulmonary
disease (COPD) [1]. Emphysema and large airway disease,
two other major pathologies in COPD, can be visualized
using chest CT scans. However, the small airways cannot
be directly imaged using current CT scan technology [2].
Traditionally, gas trapping on pulmonary function testing,
based on the ratio of either residual volume (RV) or in-
spiratory capacity to total lung capacity (TLC), has been
used as a surrogate for small airway disease. Given the
marked heterogeneity among COPD subjects and the in-
creasingly widespread use of chest CT scans in smokers
with and without COPD [3], there is a need to identify an
accurate marker of small airway disease on chest CT
scans, which may complement measures of small airway
disease derived from traditional lung function testing. The
percent of lung voxels with attenuation below a specific
threshold, such as −856 Hounsfield units (HU), on expira-
tory chest CT scans has been proposed as an indicator for
gas trapping in subjects with asthma [4]. In subjects with
COPD, this threshold method fails to distinguish gas trap-
ping due to emphysema from gas trapping due to small
airway disease (Figure 1).
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posed in subjects with COPD based on quantitative CT
analysis [5-10]. These prior studies have generally had lim-
ited sample sizes, with few subjects with either normal
lung function or severe COPD. Differentiation of gas trap-
ping due to small airway disease from emphysematous gas
trapping is especially important in subjects with more
severe COPD, who generally have more emphysema. A
recently published lung cancer screening study from the
Netherlands included inspiratory and expiratory chest CT
scans on a large sample of control smokers and subjects
with COPD, showing the independent ability of CT em-
physema and CT gas trapping measures to predict COPD
status defined by spirometry [11]. However, COPD sub-
jects were generally mild to moderate in severity, with only
a limited representation of subjects with severe COPD.
The Genetic Epidemiology of COPD Study (COPDGene)
is a large observational study of over 10,000 current and
former smokers, including subjects without airflow ob-
struction and subjects across the full range of COPD
severity [12]. We hypothesized that quantitative analysis
of paired inspiratory and expiratory chest CT scans in
COPDGene can be used to define indicators of small air-
way disease that are superior to expiratory CT imaging
alone as predictors of lung function and other COPD-
related traits in smokers across a full range of lung func-
tion values from normal to very severe COPD.
Methods
Study subjects
COPDGene recruited subjects at 21 clinical centers
across the U.S [12]. Subjects were non-Hispanic whites
or non-Hispanic African Americans ages 45–80, with a
smoking history of at least 10 pack-years. Subjects with
other diagnosed lung diseases except for asthma were
excluded. Subjects underwent a standard study visit
which included spirometry before and after albuterol ad-
ministration, measurement of exercise capacity using a
six-minute walk test, questionnaires to assess medical
history, respiratory symptoms and medication use, and a
Figure 1 Inspiratory (A,C) and expiratory (B,D) chest CT images from two subjects with similar percent of lung voxels with attenuation
values<−856HU on expiratory CT scans (Exp−856) demonstrate the inability of expiratory image analysis alone to distinguish gas
trapping due to emphysema from gas trapping due to small airway disease. Subject 1: Exp−856=38.5%, percent emphysema
(Insp−950)= 23.1%. Subject 2: Exp−856=37.1%, Insp−950=6.9%.
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(MMRC) scale was used to quantify dyspnea [13]. Disease-
related quality of life was assessed by the St. George’s
Respiratory Questionnaire (SGRQ) [14]. In COPDGene,
COPD was defined and staged according to GOLD criteria
[15], despite potential limitations of a fixed FEV1/FVC
ratio< 0.7 [16]. Study protocols and questionnaires are
a v a i l a b l ea tw w w . c o p d g e n e . o r g .T h eC O P D G e n ed a t ar e -
lease version 16-April-2012 was used for analysis. Subjects
provided written informed consent. The study was
performed in accordance with the Declaration of Helsinki
and was approved by the Institutional Review Boards at
Partners Healthcare and all participating centers.
Chest CT scans
Subjects underwent volumetric CT scans of the chest at
full inspiration (standard dose=200mAs) and at end-tidal
expiration (low dose=50 mAs). Detailed CT protocols
have been previously published [12] and are available on-
line at www.copdgene.org. CT scans were subjected to a
standard quality control procedure. Subjects with missing
or failed inspiratory or expiratory chest CT scans were
from this analysis. Computerized image analysis was
performed with 3D SLICER software (www.slicer.org)
[17,18]. Emphysema was quantified by the percent of
the lung voxels on inspiratory CT scan with attenuation
<−950 HU (Insp−950) [19]. The square root of wall area of
a hypothetical airway with 10 mm internal perimeter
(SRWA Pi10) [20], measured using VIDA software (www.
vidadiagnostics.com), was available in a minority of sub-
jects. Small airway measures on chest CT scan were de-
fined as follows:
1. Expiratory−856 (Exp−856) is defined as the percent of
the lung voxels with attenuation<−856HU on the
expiratory CT images [4]. This has been called
“percent gas trapping” in previous COPDGene
publications [21-23].
2. Expiratory to Inspiratory Ratio of Mean Lung
Attenuation (E/I MLA) is defined as the ratio of
mean lung attenuation from the density histograms
on expiratory and inspiratory scans [5-7,9,10].
3. Relative Volume Change-856 to −950 (RVC856-950) is
defined as the difference between the expiratory and
inspiratory values for relative lung volumes, which is
the limited lung volume with attenuation between −856
to 950HU divided by the lung volume without
emphysema, according to Matsuoka et al. [8] Relative
lung volume on expiratory or inspiratory scan is
expressed as:
lung volume with attenuation between −856 and -
950HU/
lung volume with attenuation> −950HU
4. Residuals are the residuals from the linear regression
of Expiratory−856 on Inspiratory−950. This statistical
approach was used to regress out the effect on
emphysema on the Expiratory−856 measure of gas
trapping.
Emphysema was considered absent in subjects with
values for Insp−950 <5%inex-smokersand<4%incurrent
smokers, to account for the fact that the increased lung
density in current smokers results in a decrease in em-
physema index [24]. Severe emphysema was defined by
Insp−950 >15% in ex-smokers and >14% in current
smokers. Total Lung Capacity (TLC) and Functional
Residual Capacity (FRC) were determined from measure-
ment of lung volumes on chest CTscans at full inspiration
and relaxed exhalation, respectively [25].
Statistical analysis
Pearson correlations were used to describe correlations
among the small airway measures and between small air-
way measures and clinical variables. Linear regression
models were used to describe the relative contributions of
emphysema and small airway disease to lung function and
selected clinical parameters. Linear regression models
were adjusted for clinically relevant covariates determined
ap r i o r i . Independent variables, including CT emphy-
sema and small airway parameters, were standardized to
mean=0 and standard deviation=1 in the regression
models. The percent of variation explained (R
2) was used
to assess the explanatory ability of a regression model.
P-value<0.05 represents statistical significance. Statistical
analyses were conducted using SAS version 9.2 (SAS
Institute, Cary, NC).
Reproducibility data
Thirty-two subjects were inadvertently enrolled twice into
COPDGene. Eighteen of those subjects had inspiratory
and expiratory chest CT scans performed with the same
protocol and passing quality control which were analyzed
with 3D SLICER. The eighteen duplicate scans were sepa-
rated by a median of 224 days (range 38–550). Spearman
correlations were used to compare the gas trapping mea-
sures in these subjects at the two time points.
Role of the funding source
The study sponsors had no role in study design; in
the collection, analysis, and interpretation of data; in the
writing of the report; and in the decision to submit
the paper for publication.
Results
COPDGene enrolled 10,300 subjects, including 108 non-
smoker controls who were excluded from this analysis.
Table 1 shows the characteristics of the 8517 current
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piratory chest CT data. Study subjects encompassed the
range of COPD severity across all GOLD stages [15].
Approximately 12% of subjects were unclassified by
GOLD, with reduced FEV1, but normal FEV1/FVC ratio;
the GOLD-unclassified subjects in COPDGene have
been described previously [26]. Surprisingly, 4% of sub-
jects with severe emphysema on chest CT scan had only
mild airflow obstruction on spirometry (GOLD1). Con-
versely, over 4% of subjects without emphysema had se-
vere or very severe airflow obstruction (GOLD 3–4).
Among the quantitative CT measures, Exp−856 was
most highly correlated with percent emphysema (Table 2,
Figure 2). E/I MLA and RVC856-950 were significantly
but less strongly correlated, while the residuals are com-
pletely uncorrelated with Insp−950, by definition. The
small airway parameters showed varying degrees of cor-
relations among themselves. Correlations between the
small airway measures and “medium-sized” airway dis-
ease indicated by SRWA Pi10 are weak, except for the
correlation with RVC856-950. In 1188 subjects with severe
emphysema, E/I MLA was less strongly correlated with
percent emphysema than were Exp−856 and RVC856-950
(r=0.40 for E/I MLA, r=0.62 for Exp−856, r=0.51 for
RVC856-950; all p<0.0001). E/I MLA was only weakly
correlated with Insp−950 in subjects without emphysema,
while Exp−856 and RVC856-950 were more highly correlated
in this group (r=0.12 for E/I MLA, r=0.50 for Exp−856,
r=−0.33 for RVC856-950; all p<0.0001).
Correlations between the small airway measures, lung
function, and other COPD-related traits are shown in
Tables 3 and 4. In all subjects, Exp−856 showed the highest
correlations with lung function measurements, including
FEV1,F E V 1/FVC and FEF25-75, a putative small airway dis-
ease marker from spirometry. E/I MLA showed a similar
correlation as Exp−856 with FEF25-75 in all subjects. FRC/
TLC ratio, a measure of hyperinflation based on chest CT
scan-derived lung volumes was most highly correlated
with E/I MLA. Exp−856, E/I MLA and RVC856-950 showed
similar correlations with SGRQ and MMRC dyspnea
score; RVC856-950 was most strongly correlated with 6-
minute walk distance (6MWD). Residuals showed the
weakest correlations with all tested traits.
In subjects with severe emphysema (Table 4), E/I MLA
and RVC856-950 were most highly correlated with all tested
traits, except for FEV1/FVC which showed a slightly higher
correlation with Exp−856. Again, residuals showed the
poorest correlations with lung function, 6-minute walk
distance and symptoms. In subjects without significant em-
physema (Additional file 1: Table S1), RVC856-950 or
E/I MLA generally showed the strongest correlations. E/I
MLA was most highly correlated with FEV1/FVC, FEF25-75
and FRC/TLC ratio. Residuals generally showed the
weakest correlations with all tested outcomes.
Table 1 COPDGene study subjects
All subjects Severe emphysema‡ No emphysema§
N 8517 1188 5769
Age 59.6 (9.0) 65.5 (7.7) 57.6 (8.6)
Sex
Male 4535 (53.2%) 711 (59.8%) 2849 (49.4%)
Female 3982 (46.8%) 477 (40.2%) 2920 (50.6%)
Race
African American 2668 (31.3%) 190 (16.0%) 2156 (37.4%)
White 5849 (68.7%) 998 (84.0%) 3613 (62.6%)
Current smoking 4463 (52.4%) 259 (21.8%) 3547 (61.5%)
Pack-years of smoking 44.3 (24.8) 55.4 (27.8) 40.8 (22.6)
GOLD Stage [54 missing]† [3 missing]† [40 missing]†
0 3674 (43.4%) 17 (1.4%) 3241 (56.6%)
1 668 (7.9%) 47 (4.0%) 414 (7.2%)
2 1636 (19.3%) 263 (22.2%) 870 (15.2%)
3 965 (11.4%) 458 (38.7%) 217 (3.8%)
4 502 (5.9%) 396 (33.4%) 33 (0.6%)
Unclassified* 1018 (12.0%) 4 (0.3%) 954 (16.7%)
Non-smokers were excluded. Mean (SD) or N (%) is shown.
*Unclassified: FEV1 < 80% predicted with FEV1/FVC > 0.7.
†GOLD Stage is missing in subjects whose spirometry failed quality control.
‡Severe emphysema defined by Insp-950HU> 15% ex-smokers, > 14% current smokers.
§No emphysema defined by Insp-950HU < 5% ex-smokers, < 4% current smokers.
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and each of three small airway measures (Exp−856,E / I
MLA, and RVC856-950) on the COPD-related traits FEV1,
FEV1/FVC, FEF25-75, 6-minute walk distance and SGRQ.
Residuals were not used in the regression analysis due to
consistently weak correlations in the earlier analyses. Em-
physema and gas trapping variables were standardized, so
the regression coefficients reflect the effect of a one stand-
ard deviation change in each CT variable. Based on
percent variation explained (R
2), all three small airway
measures were equally predictive of FEV1. The effects of
emphysema and gas trapping on FEV1 were equivalent
when either E/I MLA or RVC856-950 were used as the gas
trapping measure, whereas the gas trapping variable
exerted more than three times the effect of emphysema
(−0.45 L vs. -0.11 L) in the model using Exp−856.M o d e l s
including either Exp−856 or E/I MLA explained more of
the variation in FEV1/FVC and in FEF25-75 than the model
Table 2 Correlations between quantitative CT measures in COPDGene subjects
Correlations
N Mean(SD) %emph
Insp -950
Exp -856 E/I mean
lung atten.
RVC 856–950 Residuals SWRA Pi10
%emphysema Insp -950 8517 6.2 (9.7) --
%Exp -856 8517 21.9 (19.9) 0.83† --
E/I mean lung attenuation 8517 0.87 (0.07) 0.51† 0.80† --
RVC 856–950 8517 −0.37 (0.18) 0.37† 0.48† 0.58† --
Residuals 8517 0 (11.2) 0 0.56† 0.67† 0.32† --
SRWA Pi10 (mm) 2867 3.75 (0.12) 0.06* 0.13† 0.23† 0.46† 0.15† --
Pearson correlation coefficients are shown.
*p< 0.01.
†p< 0.0001.
Figure 2 Scatterplots of four gas trapping measurements vs. percent emphysema (see Methods for definitions).
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were similar in models predicting 6MWD and SGRQ
score in all subjects.
In subjects with severe emphysema (Table 6), models
with E/I MLA or RVC856-950 were better predictors of
FEV1 than was Exp−856. Only the model using E/I MLA
captured significant effects from both emphysema and gas
trapping variables. All three small airway measures yielded
s i m i l a r l yp r e d i c t i v em o d e l sf o rF E V 1/FVC, FEF25-75,
6MWD, and SGRQ. In the analysis of 6MWD, use of
Exp−856 led to a significant positive effect of gas trapping,
meaning an increase in the gas trapping variable corres-
ponded to an increase in 6MWD among severe emphy-
sema subjects. The 6MWD models with E/I MLA or
RVC856-950 captured significant effects of emphysema only,
with an expected direction of effect, namely reduction in
6MWD. Both E/I MLA and RVC856-950 identified statisti-
cally significant effects of gas trapping on SGRQ score in
subjects with severe emphysema.
In subjects without significant emphysema, models
including each of the small airway measures explained simi-
lar fractions of the variation in the COPD-related traits,
with the exception of RVC856-950 predicting FEV1/FVC
(Additional file 2: Table S2). In these subjects, quantitative
emphysema measurements were not significantly associated
with FEV1,F E V 1/FVC or 6MWD when E/I MLA was used
as the gas trapping indicator.
In the eighteen subjects with repeat quantitative CT
data, the gas trapping measures from the two time
points were significantly correlated within each subject:
Exp−856 ρ =0.79, p<0.0001; E/I MLA ρ=0.67, p =0.002;
RVC856-950 ρ =0.54, p= 0.02.
Discussion
In the largest cohort of smokers with quantitative chest
CT data published to date, we evaluated four variables
to measure gas trapping as a surrogate for small airway
disease, since the airways of interest are below the
Table 3 Correlations between gas trapping measures and quantitative outcomes in all subjects
Correlations
N Mean (SD) Exp−856 E/I MLA RVC856-950 Residual
FEV1 % predicted 8463 76.6 (25.5) −0.69* −0.60* −0.54* −0.33*
FVC % predicted 8463 87.2 (18.2) −0.33* −0.32* −0.44* −0.18*
FEV1/FVC 8463 0.67 (0.16) −0.82* −0.67* −0.41* −0.37*
FEF25-75 8463 1.75 (1.25) −0.60* −0.59* −0.38* −0.36*
FRC/TLC ratio 8517 0.58 (0.13) 0.65* 0.89* 0.76* 0.65*
6MWD 8407 1363 (397) −0.32* −0.34* −0.46* −0.18*
Exacerbation frequency 8517 0.4 (0.9) 0.26* 0.22* 0.19* 0.12*
SGRQ total 8517 27.0 (22.8) 0.39* 0.36* 0.43* 0.20*
MMRC dyspnea 8506 1.3 (1.4) 0.36* 0.32* 0.42* 0.15*
Pearson correlation coefficients are shown.
*p< 0.0001.
Table 4 Correlations between gas trapping measures and quantitative outcomes in subjects with severe emphysema
(Insp-950HU >15% ex-smokers, Insp-950HU > 14% current smokers)
Correlations
N Mean (SD) Exp−856 E/I MLA RVC856-950 Residual
FEV1 % predicted 1185 41.2 (19.9) −0.69‡ −0.73‡ −0.73‡ −0.16‡
FVC % predicted 1185 75.7 (21.1) −0.49‡ −0.56‡ −0.57‡ −0.17‡
FEV1/FVC 1185 0.40 (0.12) −0.66‡ −0.62‡ −0.62‡ −0.08*
FEF25-75 1185 0.42 (0.38) −0.56‡ −0.61‡ −0.61‡ −0.18‡
FRC/TLC ratio 1188 0.69 (0.12) 0.80* 0.93* 0.87* 0.44*
6MWD 1135 1116 (404) −0.31‡ −0.40‡ −0.43‡ −0.01
NS
Exacerbation frequency 1188 0.8 (1.2) 0.10† 0.12‡ 0.13‡ −0.02
NS
SGRQ total 1188 44.9 (19.9) 0.32‡ 0.41‡ 0.43‡ 0.09*
MMRC dyspnea 1183 2.5 (1.3) 0.34‡ 0.38‡ 0.42‡ 0.01
NS
Pearson correlation coefficients are shown.
*p< 0.01.
†p< 0.001.
‡p< 0.0001.
NS = not significant (p > 0.05).
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defined in an effort to separate gas trapping due to small
airway disease from gas trapping due to emphysema.
The residuals from regression of expiratory air trapping
on emphysema showed consistently poor correlations
and were not tested in multivariable models. In general,
the other three measures – percent of lung with attenu-
ation <−856HU on expiratory chest CT scan, the expira-
tory to inspiratory ratio of mean lung attenuation, and
the relative volume change856-950 – were similarly
predictive of lung function, exercise capacity and quality
of life when all subjects were considered together (Table 5).
However, in subjects with severe emphysema, the two
measures that utilized paired inspiratory and expiratory
CT scans – E/I MLA and RVC856-950 – yielded more pre-
dictive associations (Table 6). The paired measures
performed adequately in subjects without significant em-
physema as well (Additional file 2: Table S2). The variables
had reasonable reproducibility in a small subset of sub-
jects with duplicate chest CT scans, although repeat
Table 5 Regression models for lung function, exercise capacity and symptoms in all subjects
A. Linear regression for FEV1 (L)
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) −0.11 <0.0001 −0.31 <0.0001 −0.29 < 0.0001
Gas Trapping variable† −0.45 <0.0001 −0.30 <0.0001 −0.30 < 0.0001
Model fit statistics
R
2 0.67 0.68 0.68
B. Linear regression for FEV1/FVC
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) −0.03 <0.0001 −0.09 <0.0001 −0.10 < 0.0001
Gas Trapping variable† −0.10 <0.0001 −0.06 <0.0001 −0.03 < 0.0001
Model fit statistics
R
2 0.73 0.70 0.64
C. Linear regression for FEF25-75
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) 0.0002 0.99 −0.29 <0.0001 −0.38 < 0.0001
Gas Trapping variable† −0.68 <0.0001 −0.51 <0.0001 −0.24 < 0.0001
Model fit statistics
R2 0.50 0.52 0.45
D. Linear regression for 6-minute walk distance (ft).
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) −47.8 <0.0001 −46.3 <0.0001 −37.3 < 0.0001
Gas Trapping variable† −3.7 0.6 −22.0 <0.0001 −51.8 < 0.0001
Model fit statistics
R
2 0.44 0.44 0.45
E. Linear regression for SGRQ Total score.
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) 1.3 0.0004 2.8 <0.0001 2.7 < 0.0001
Gas Trapping variable† 3.2 <0.0001 1.9 <0.0001 1.7 < 0.0001
Model fit statistics
R
2 0.42 0.42 0.42
All models are adjusted for age, sex, race, clinical center, current smoking status, pack-years of smoking, height, weight, Siemens 64 scanner. Models for 6-minute
walk distance (D) and SGRQ score (E) were additionally adjusted for FEV1% predicted.
*Independent variables standardized to mean = 0 and SD= 1. β = change in dependent variable, e.g. FEV1 (L), for each SD change in independent variable.
†Either Exp−856, E/I mean lung attenuation ratio, or RVC856-950.
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RVC856-950, since the latter two measures incorporate vari-
ability from both inspiratory and expiratory acquisitions.
Assessment of low attenuation areas on expiratory
chest CT scans was initially described as a marker for
gas trapping in studies of asthma [27]. The Severe
Asthma Research Program proposed the threshold of -
856HU [4]. As opposed to asthma, in COPD both em-
physema and gas trapping from small airway disease
may lead to increased values for Exp−856.
Several groups have examined paired inspiratory and
expiratory CT scan measures of gas trapping in COPD.
The majority of papers have used the expiratory to in-
spiratory ratio of mean lung attenuation, which has also
been referred to as the ratio of mean lung density
[5-7,10]. Matsuoka and colleagues defined RVC850-950
[8], similar to RVC856-950 in the current analysis. These
previous studies have found good correlations between
pulmonary function measures and gas trapping. How-
ever, the sample sizes in the published papers have
Table 6 Regression models for lung function, exercise capacity and symptoms in subjects with severe emphysema
A. Linear regression for FEV1 (L)
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) 0.01 0.5 −0.08 <0.0001 −0.01 0.3
Gas Trapping variable† −0.46 < 0.0001 −0.43 <0.0001 −0.46 < 0.0001
Model fit statistics
R
2 0.63 0.68 0.67
B. Linear regression for FEV1/FVC
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) −0.01 0.004 −0.03 <0.0001 −0.02 < 0.0001
Gas Trapping variable† −0.08 < 0.0001 −0.07 <0.0001 −0.07 < 0.0001
Model fit statistics
R
2 0.52 0.52 0.49
C. Linear regression for FEF25-75
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) 0.01 0.3 −0.04 0.0001 −0.004 0.7
Gas Trapping variable† −0.24 < 0.0001 −0.23 <0.0001 −0.24 < 0.0001
Model fit statistics
R
2 0.46 0.50 0.49
D. Linear regression for 6-minute walk distance (ft).
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) −66.6 < 0.0001 −51.7 <0.0001 −46.6 0.0002
Gas Trapping variable† 41.4 0.01 −3.4 0.8 −22.4 0.2
Model fit statistics
R
2 0.41 0.41 0.41
E. Linear regression for SGRQ Total score.
Exp−856 E/I MLA RVC856-950
Independent variables β* p-value β* p-value β* p-value
% emphysema (Insp−950) 0.9 0.2 0.9 0.1 0.1 0.8
Gas Trapping variable† 1.1 0.2 3.0 0.0001 4.4 < 0.0001
Model fit statistics
R
2 0.34 0.35 0.36
All models are adjusted for age, sex, race, clinical center, current smoking status, pack-years of smoking, height, weight, Siemens 64 scanner. Models for 6-minute
walk distance (D) and SGRQ score (E) were additionally adjusted for FEV1% predicted.
*Independent variables standardized to mean = 0 and SD= 1. β = change in dependent variable, e.g. FEV1 (L), for each SD change in independent variable.
†Either Exp−856, E/I mean lung attenuation ratio, or RVC856-950.
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considered a single gas trapping metric. Mets and
colleagues compared several different gas trapping mea-
sures in 248 subjects [9]. Similar to our analysis, they
found that the two paired measures – E/I MLA and
RVC860-950 in their study – had the strongest correlations
with lung function. We confirmed these findings in a
much larger cohort, and found parallel correlations with
important clinical outcomes including exercise capacity
and quality of life. Most of the previous papers performed
expiratory CT scans at full expiration (RV), whereas
COPDGene scans were performed at end-tidal expiration,
corresponding to FRC.
A recently published Dutch lung cancer screening study
acquired low-dose inspiratory and end-expiratory chest
CT scans in 1140 male smokers at a single center [11]. A
multivariable model which included both CT emphysema
(Insp−950) and E/I MLA as a marker of gas trapping was
highly accurate in predicting COPD. Although 437 (38%)
subjects had COPD based on spirometry, only 25 subjects
had severe COPD (GOLD 3) and none had very severe
COPD (GOLD 4).
The large number of subjects with quantitative analysis
of inspiratory and expiratory chest CT scans is one of the
strengths of the COPDGene study. The sample size in
COPDGene is nearly ten times as large as the Dutch can-
cer screening study [11]. COPDGene included smokers
with normal lung function and with the full range of lung
function impairment, in contrast to previous papers. In-
cluding subjects with severe and very severe COPD
(GOLD 3–4) allowed for the analysis in subjects with se-
vere emphysema, though emphysema severity did not
completely correlate with GOLD stage. The extensive cli-
nical characterization in COPDGene allowed us to select a
range of COPD-related traits including spirometry, exer-
cise capacity and disease related quality of life. Subjects in
COPDGene were enrolled at multiple clinical centers and
underwent CT scans on different scanner models, yet we
were able to find robust associations which were appli-
cable across the multi-center study.
Ideally, one would test the CT measures of small air-
way disease against physiologic measures that have been
traditionally used to measure small airway disease,
including the RV/TLC ratio. However, lung volumes
were not measured by pulmonary function testing in
COPDGene, but were assessed on chest CT scans. E/I
MLA showed the strongest correlation with the CT-
derived FRC/TLC ratio, a marker of hyperinflation.
Study subjects were given standard instructions for
breath-holds at full inspiration (TLC) and end-tidal ex-
piration (FRC), but the chest CT scans did not use spi-
rometric gating to ensure compliance. The CT scanning
protocol in COPDGene more accurately reflects clinical
practice and still provides important information in the
research setting. We did find significant correlations
with FEF25-75, a putative small airway disease measure-
ment on spirometry. Measurement of carbon monoxide
diffusing capacity (DLCO) can be used as an indicator
of emphysema on pulmonary function testing; however
DLCO was not measured in the COPDGene Study. The
CT measures may complement standard lung function
testing in the evaluation of COPD patients.
Besides histology, direct visualization of the small air-
ways would be the optimal metric for small airway disease
in smokers. This can be performed ex vivo using microCT
[28], but is not feasible in living patients. There is substan-
tial literature using measurements of airway disease in
larger airways, such as SRWA Pi10 [20]. Papers from
COPDGene have found correlations between segmental
and subsegmental airway wall measures and clinical traits
including exacerbations [29], chronic bronchitis [30],
pulmonary function [31] and quality of life [32]. These
approaches rely on the assumption that similar patho-
logical processes are occurring in the small airways and
the more proximal airways. At present, the choice of the
best airway wall measurement is not clear, and any such
measure on the larger airways is primarily a surrogate for
small airway disease. Pairing standard inspiratory chest
CT scans with low dose expiratory scans can provide an
alternative marker for airflow obstruction in the small
airways in smokers, yet most large COPD studies do not
acquire expiratory CTscans [33,34].
Conclusions
We have shown that two previously-described gas trap-
ping measures based on paired inspiratory and expiratory
chest CT scans (E/I MLA and RVC856-950) may serve as
markers of small airway disease in smokers, including
subjects with severe and very severe COPD. Although we
cannot claim that one measure is superior to the other,
the expiratory to inspiratory ratio of mean lung attenu-
ation may be more straightforward than RVC856-950,a n d
has more support in the published COPD literature. For
clinical applicability, it will be important to define thresh-
olds for these gas trapping parameters that delineate
normal from small airway disease; a large sample of never
smokers with normal lung function is necessary for
this effort. Additionally, thresholds to define airway-
predominant vs. emphysema-predominant COPD sub-
types are also desirable. The current data do not allow
for assessment of changes in these measures with treat-
ment, an important area for future investigation. Large
studies of smokers will have to include expiratory CT
scans to further these efforts. In COPDGene and future
studies, these gas trapping variables can be used in gen-
etic analyses, to better understand the pathobiology of
COPD subtypes.
Hersh et al. Respiratory Research 2013, 14:42 Page 9 of 11
http://respiratory-research.com/content/14/1/42Additional files
Additional file 1: Table S1. Correlations between gas trapping
measures and quantitative outcomes in subjects without emphysema
(Insp-950< 5% ex-smokers, < 4% current smokers).
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